Plant Name: Arachniodes exilis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.306E-09 | 3.182E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.042E-08 | 3.242E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 1.383E-08 | 3.346E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP5, KLF5, LMNA, PPARA, PPARD, SMN1, SMN2, STAT3, TLR2, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.134E-07 | 1.319E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.212E-07 | 1.319E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.248E-06 | 9.367E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 1.095E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.152E-06 | 1.266E-03 | PPARD, STAT3, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 4.244E-06 | 2.100E-03 | CYP1B1, FABP3, LMNA, PPARD, STAT3, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 5.247E-06 | 2.380E-03 | CYP1A1, CYP1A2, CYP1B1, KLF5, STAT3, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 2.712E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.209E-06 | 3.438E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 1.572E-05 | 6.067E-03 | CYP1A1, CYP1B1, FABP4, KLF5, PPARD, STAT3, TP53, TSHR |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.697E-05 | 6.241E-03 | PPARA, PPARD, STAT3 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.981E-05 | 6.847E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 2.132E-05 | 7.143E-03 | PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.841E-05 | 9.234E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0070491; repressing transcription factor binding | 3.128E-05 | 9.731E-03 | GMNN, PPARA, STAT3 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.037E-11 | 4.080E-09 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.979E-07 | 1.207E-05 | CYP1A2; CYP1A1; CYP1B1; CYP19A1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.252E-06 | 2.228E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.627E-05 | 3.294E-04 | CYP1A1; CYP1B1; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.086E-05 | 8.240E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.914E-04 | 2.214E-03 | STAT3; CYP1B1; TP53; CDC25B |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.201E-05 | 9.721E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.017E-04 | 2.899E-03 | STAT3; PPARA; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.966E-04 | 3.213E-03 | STAT3; TP53; TLR2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.221E-04 | 2.899E-03 | STAT3; TP53; TLR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.034E-03 | 7.614E-03 | STAT3; TP53; TLR2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.467E-03 | 9.141E-03 | STAT3; PPARD |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.416E-03 | 9.141E-03 | FABP4; TSHR |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.903E-03 | 9.928E-03 | STAT3; TLR2 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.961E-03 | 9.928E-03 | STAT3; TP53 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.903E-03 | 9.928E-03 | CYP1A2; CYP1A1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.203E-03 | 1.050E-02 | STAT3; PPARA |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.885E-03 | 2.535E-02 | STAT3; TP53; PPARD |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.245E-03 | 2.236E-02 | STAT3; PPARA |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 6.118E-03 | 2.478E-02 | STAT3; TLR2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.511E-03 | 2.952E-02 | LMNA; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 8.746E-03 | 2.952E-02 | TP53; PPARD |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.735E-03 | 2.535E-02 | TP53; CDC25B |
| hsa03013 | RNA transport_Homo sapiens_hsa03013 | 1.262E-02 | 4.089E-02 | SMN2; SMN1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.664E-02 | 4.914E-02 | PPARA; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.711E-02 | 4.914E-02 | STAT3; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.759E-02 | 4.914E-02 | STAT3; TP53 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.449E-02 | 4.515E-02 | TP53; TLR2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.991E-03 | 2.236E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | STAT3 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | STAT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | STAT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CDC25B; STAT3; TLR2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; STAT3; TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |